PRVL News and Press, Prevail Therapeutics Inc. From 02/12/20

Orphan Drug Designation Granted for Treatment of Gaucher Disease  Rare Pediatric Disease Designation Granted for Treatment of Neuronopathic Gaucher Disease NEW YORK, Feb. 12, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL) (“Prevail” or the...

NEW YORK, Feb. 06, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL) (“Prevail” or the “Company”), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases, today announ...

Quick Take Passage Bio ( PASG ) has filed to raise $125 million in an IPO of its common stock, according to an S-1 registration statement . The firm is developing genetic treatments for monogenic (single gene) central nervous system [CNS] health conditions. PASG is at pre-clinical stage...

PR001 Administered to International Type 2 Gaucher Disease Patient  Via Compassionate Use Pathway Company Advancing its Phase 1/2 Clinical Trial for the Treatment of Neuronopathic Gaucher Disease and Expects to Initiate Patient Dosing in First Half of 2020 NEW YORK, Jan. 09,...

The FDA has notified Prevail Therapeutics (NASDAQ: PRVL ) that its Investigational New Drug (IND) application for PR001 for the treatment of neuronopathic Gaucher disease (nGD) patients is now active and that Prevail may proceed with initiating its proposed clinical trial. More news...

NEW YORK, Dec. 26, 2019 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL) (“Prevail” or the “Company”), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases, today announ...

Gainers: PRVL   +15.8% . NOAH   +2.8% . SFUN   +2.4% . ODP   +2.3% . HEI   +2.2% . More news on: Prevail Therapeutics Inc., Noah Holdings Limited, Fang Holdings Limited, Stocks on the move, , News on ETFs Read more ...

NEW YORK, Dec. 16, 2019 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases, announced today that the U.S. Food and Drug Administration (FDA) has ...

The following slide deck was published by Prevail Therapeutics Inc. in conjunction with this Read more ...

NEW YORK, Nov. 18, 2019 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases, today announced the appointment of Morgan Sheng, Ph.D., to its Board ...